Your browser doesn't support javascript.
loading
Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.
Naismith, Robert T; Hendin, Barry; Wray, Sibyl; Huang, DeRen; Gaudenzi, Fiorenza; Dong, Qunming; Sperling, Bjørn; Mann, Monica; Werneburg, Brian.
Affiliation
  • Naismith RT; Department of Neurology, Washington University in St Louis, USA.
  • Hendin B; Phoenix Neurological Associates, USA.
  • Wray S; Hope Neurology, USA.
  • Huang D; Mount Carmel Neuroscience and MDH Research, USA.
  • Gaudenzi F; Biogen, USA.
  • Dong Q; Biogen, USA.
  • Sperling B; Biogen, USA.
  • Mann M; Biogen, USA.
  • Werneburg B; Biogen, USA.
Mult Scler J Exp Transl Clin ; 5(1): 2055217318822148, 2019.
Article in En | MEDLINE | ID: mdl-30729026
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Language: En Journal: Mult Scler J Exp Transl Clin Year: 2019 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Language: En Journal: Mult Scler J Exp Transl Clin Year: 2019 Type: Article Affiliation country: United States